Bellicum Pharmaceuticals, Inc. (BLCM) News
Filter BLCM News Items
BLCM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest BLCM News From Around the Web
Below are the latest news stories about BELLICUM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate BLCM as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off the day with the biggest pre-market stock movers traders will want to keep in mind while trading on Tuesday! |
Why Is Immuron (IMRN) Stock Up 67% Today?Immuron (IMRN) stock is gaining on Monday thanks to an update from the Food and Drug Administration (FDA) on a clinical hold. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayPre-market stock movers are a hot topic on Monday as we dive into the biggest winners and losers traders need to know about this morning! |
Why Is Aptorum (APM) Stock Down 16% Today?Aptorum (APM) stock is falling on Monday after the biopharmaceutical company received a delisting notice from the Nasdaq. |
Why Is Bellicum Pharmaceuticals (BLCM) Stock Up 75% Today?Bellicum Pharmaceuticals (BLCM) stock is rising higher on Monday morning following news of an investment in the company. |
Why Is Tupperware Brands (TUP) Stock Down 8% Today?Tupperware Brands (TUP) stock is taking a beating on Monday after the company said it's exploring strategic alternatives. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayThe biggest pre-market stock movers are a hot topic traders are going to want to know about with all the latest news on Friday! |
Bellicum (BLCM) Down on Ending Development of CAR-T CandidatesFollowing the decision to discontinue the development of pipeline candidates, Bellicum Pharmaceuticals (BLCM) is left with no candidate in clinical development. The stock is down 50% post the news. |
Is Bellicum Pharmaceuticals (BLCM) Stock Outpacing Its Medical Peers This Year?Here is how Bellicum Pharmaceuticals (BLCM) and Chemed (CHE) have performed compared to their sector so far this year. |
Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic AlternativesHOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. The trials for BPX-601 and BPX-603 are being discontinued following the Company’s assessment of the risk/benefit profile of BPX-601 in combination with rimiducid. The most |